Singapore eDevelopment initiates research on Universal Drug Platform

22-May-17 Singapore eDevelopment has initiated research on a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Daryl Thompson. [image: ET Healthworld / BBCL]

Singapore eDevelopment initiates research on Universal Drug Platform

 22-May-17, ET Healthworld

Singapore eDevelopment (SeD), through its subsidiary Global BioLife has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee, Daryl Thompson.

Image: ET Healthworld / BBCL

Singapore Exchange-listed SeD said Daryl Thompson will leverage on his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the research and development of this universal therapeutic drug platform.

Unlike the traditional approach to cure individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Latest

About us

GGM is a research and advisory firm helping clients grow profitably in international markets.

We believe the only way to understand a market properly is on the ground. Intelligence from our in-country consultants gives you a competitive advantage in China, Asia, Latin America, the Middle East, Africa and other opportunity areas.

Our clients benefit from accurate data, reliable insights and strategic advice, giving them the confidence to make better business decisions and succeed in their global growth markets.

Stay informed

Enter your work email to receive our free GROW newsletter on international market intelligence and strategy.